AstraZeneca to supply 400 million of potential vaccine to Europe

▴ astrazeneca-supply-400-million-potential-vaccine-europe
Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy, and also the Netherlands to secure vaccine doses for all its member States soon

UK Pharma company AstraZeneca Plc has come in a contract with European governments to provide its potential vaccine against the Coronavirus to assist combat the pandemic.
The contract is for up to 400 million doses of the vaccine, developed by the University of Oxford, the company reportedly said on Saturday, adding that it had been looking to expand the manufacturing of the vaccine, which it said it might provide for no profit during the pandemic. The vaccine remains in clinical trials. If the trial results convince regulators the vaccine is safe and effective, deliveries would be expected to start out by 2020 end.
The deal thus inscribes that Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy, and also the Netherlands to secure vaccine doses for all its member States soon.

"This will make sure that hundreds of millions of people in Europe will have access to the present vaccine, in fact, if it works and that we will know that by summer-end," the company's chief executive, Pascal Soriot was quoted as saying to the journalists. He said he has "good hope" that it'll work, supported initial data.
The alliance "will work alongside the European Commission and other countries in Europe to make sure everybody across Europe is provided with the vaccine," he said.
"We have a really self-sufficient supply chain for Europe" with manufacturers lined up within the Netherlands, Germany, Italy, and Italy, among others, he further said.


The vaccines are for all EU member states. The four nations that agreed the deal can pay for the entire amount, which has not been disclosed, and therefore the scheme allows other countries to hitch it under equivalent conditions, a source from the Italian health ministry said.
Apparently, China, Brazil, Japan, and Russia have also shown interest in this vaccine.
It has got the green signal from The British Medicines and Healthcare products regulatory authority (MHRA) kick start the phase III clinical trial of the vaccine after studies suggest sufficient efficacy and safety, Soriot reportedly said.
At a gathering of EU Health Ministers on Friday, IVA apparently agreed to merge its activities with those of the EU Commission, Germany's Health Ministry said.
It has agreed on the manufacturing of manufacturing 2 billion doses of the vaccine to serve its target beneficiaries along with two Bill Gates-backed ventures and a $1.2 billion agreement with the United States government.
The deal will add an extra 100 million doses to the two billion already committed by the group, AstraZeneca said.
There are not any approved vaccines or treatments for COVID-19, the highly contagious respiratory disease caused by the novel coronavirus.
"Many countries within the world have already secured vaccines, Europe has not yet. The rapid coordinated action of a gaggle of member states will create added value for all EU citizens during this crisis," Italian Health Minister Roberto Speranza was quoted as saying

Tags : #Coronavirus #Vaccine #Astrazeneca #Europe #China #Brazil #BillGates

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

The Value of Risk Communication in Public HealthOctober 08, 2026
What Makes a Reliable Health Screening Programme?October 08, 2026
How Language Access Can Improve Patient Communication in Indian HealthcareOctober 07, 2026
Why Health Literacy Matters in Preventive HealthcareOctober 07, 2026
Improving Follow-Up After Diagnostic Testing: Where Systems Commonly Break DownOctober 07, 2026
Improving Follow-Up After Diagnostic Testing: Where Systems Commonly Break DownOctober 07, 2026
How Community Health Workers Support Preventive Care DeliveryOctober 07, 2026
AI in India's Emergency Departments: Reducing Diagnostic DelaysOctober 06, 2026
AI and Patient Consent in India: Who Is Responsible?October 06, 2026
Wearable Technology in Pregnancy: Benefits and LimitsOctober 06, 2026
Remote Monitoring for High-Risk Pregnancies in IndiaOctober 06, 2026
Fortis Escorts Faridabad Launches ‘Sehat Express’ Mobile Bus for Accessible Doorstep Cancer Screening in association with Faridabad Industries Association Charitable Society and Rotary Club FaridabadOctober 05, 2026
Advanced Thrombectomy Saves 60-Year-Old Woman After Severe Heart Attack at KIMS SaveeraOctober 05, 2026
Constipation, Bloating and Long Sitting Hours: Doctors at RG Hospitals Delhi Warn Urban Professionals Not to Ignore Gut ProblemsOctober 05, 2026
Fermenta – Centre of Excellence for Food Fortification Inaugurated at NIFTEM-T, ThanjavurOctober 05, 2026
Alzheimer’s Dementia: Recognising the Signs, Diagnosing Earlier and Changing the Future of Brain HealthOctober 05, 2026
Man Matters Hairfall Case Study 2026: 7 Lakh+ Consultations Reveal How Hair Loss Changes With AgeOctober 05, 2026
Medication Reconciliation: A System-Level Step for Safer Transitions of CareOctober 05, 2026
The Role of Clinical Pharmacists in Safer Medication UseOctober 05, 2026
Nanavati Max Hospital Hosts Max Cancer Congress 2026, Bringing Together Oncology Experts to Explore the Future of Cancer Care October 01, 2026